Biogen expects “minimal” revenue this year from its Alzheimer’s treatment initially hailed as potentially a breakthrough drug, but one with an eye-popping price tag that drew immediate criticism from doctors and patient advocates.
The drugmaker on Thursday released a forecast for 2022 that caught investors off guard, sending shares down more than 3% before the opening bell.
